Mount Sinai Doctors Elected to National Academy of Medicine for Contributions to Emergency Medicine and Translational Genetics
Brendan G. Carr, MD, MA, MS, Chair of Emergency Medicine for the Icahn School of Medicine at Mount Sinai and the Mount Sinai Health System, and Judy H. Cho, MD, Dean of Translational Genetics at the Icahn School of Medicine at Mount Sinai and Director of The Charles Bronfman Institute for Personalized Medicine, have been elected to the National Academy of Medicine (NAM). Election to the NAM is considered one of the highest honors in health and medicine, recognizing individuals who have demonstrated outstanding professional achievement and commitment to service. With their election, Mount Sinai has 25 faculty members in the NAM.
“The recognitions of Dr. Carr and Dr. Cho are well deserved for their groundbreaking contributions to emergency medicine and translational genetics,” says Dennis S. Charney, MD, Anne and Joel Ehrenkranz Dean of the Icahn School of Medicine at Mount Sinai. “Dr. Carr’s research has focused not only on improving the emergency care system for time-sensitive conditions such as trauma, stroke, cardiac arrest, and sepsis, but also on creating a more distributed and innovative approach to increasing access to acute care. Likewise, Dr. Cho is committed to improving care through personalized medicine and the understanding of each patient’s unique genes. She has enhanced genetic research, clinical implementation, and data platforms to ensure Mount Sinai remains at the forefront of genetic discoveries and implementation.”
Emergency Medicine
A leading voice in emergency medicine, Dr. Carr played a central role in coordinating Mount Sinai’s response to the COVID-19 pandemic. He has dedicated his career as an emergency medicine physician and health policy researcher to seamlessly combining research, policy, and practice to advance acute care delivery. Before joining Mount Sinai in February 2020, Dr. Carr held faculty positions at the Sidney Kimmel Medical College at Thomas Jefferson University and the Perelman School of Medicine at the University of Pennsylvania.
Outside academia, Dr. Carr has worked within the U.S. Department of Health and Human Services during both the current and previous administrations to improve trauma and emergency care services at the national level. His roles have included Senior Advisor and Director of the Emergency Care Coordination Center within the Office of the Assistant Secretary for Preparedness and Response, focusing on integrating the emergency care system into the broader health care delivery system. He previously supported the Indian Health Service’s initiatives to improve emergency care delivery, and worked with the Department of Veterans Affairs and the Department of Defense to integrate military and civilian health care response during disasters and public health emergencies. Dr. Carr has advised and supported major not-for-profit foundations, the World Health Organization, and the National Academy of Medicine.
He conducts health services research that connects disciplines including epidemiology, health care policy, business, economics, and health care delivery system science. His work has been continuously funded by the National Institutes of Health, the Centers for Disease Control and Prevention, and the Agency for Healthcare Research and Quality. He has published and lectured widely on systems of care for trauma, stroke, cardiac arrest, and sepsis.
“I’ve spent my career focused on improving access to high-quality emergency care and am extremely humbled to be recognized by my peers with this honor. The recent COVID-19 surge reminded us of the importance of building robust systems that meet the needs of the communities that we serve. I’m incredibly grateful for the opportunities I’ve been given and the mentors that have helped to guide my career,” says Dr. Carr. “I am particularly grateful to be honored alongside my Mount Sinai colleague.”
Translational Genetics
Dr. Cho is an internationally recognized expert on the genetics and genomics of inflammatory bowel disease. As Dean of Translational Genetics, she leads strategic planning and integration of translational genetics research and care across school departments and institutes, with a focus on the rapid application of genetic and genomic discoveries to improve patient care. She also holds the Ward-Coleman Chair in Translational Genetics as well as professorships in Genetics and Genomic Sciences, and Medicine.
In 2013, Dr. Cho joined the Icahn School of Medicine faculty following appointments at the Yale University School of Medicine and the University of Chicago Pritzker School of Medicine. For the past five years, she has been Director of The Charles Bronfman Institute for Personalized Medicine and overseen the BioMe Biobank program, a pioneer in the movement toward diagnosis and classification of disease according to the patient’s molecular profile.
“Science generally, and genetics especially, is a team sport; this recognition reflects many, many close collaborations over the years,” says Dr. Cho. “It is a privilege to try to advance science to help patients, and genetic discovery provides a particularly powerful means of prioritizing novel therapeutic targets.”
Dr. Cho also leads an independent research program that is generously funded by the National Institutes of Health (NIH) and other extramural sources, and chairs the External Advisory Committee of the Wellcome Trust Centers for Human Genetics and Cellular Genetics. She has been Principal Investigator of the Data Coordinating Center for the Inflammatory Bowel Disease Genetics Consortium of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) since 2002 and chaired its Steering Committee for 16 years. Previously, she served on the American Society for Clinical Investigation Council and the NIDDK External Advisory Council, and chaired the Genetics of Health and Disease Study Section at the NIH. In 2014, Dr. Cho received the Crohn’s and Colitis Foundation’s Lifetime Achievement Award in Basic Science.
New members are elected to the NAM by current, active members through a selective process that recognizes leaders making major contributions to the advancement of the medical sciences, health care, and public health. Established in 1970 by the National Academy of Sciences, NAM is a national resource that provides independent, objective analysis and advice on health issues.
The elections of Dr. Carr and Dr. Cho bring Mount Sinai’s total membership in the prestigious group to 25 current and emeritus faculty members: Joseph D. Buxbaum, PhD • Neil S. Calman, MD, MMS • Dennis S. Charney, MD • Kenneth L. Davis, MD • Robert J. Desnick, MD, PhD • Angela Diaz, MD, MPH • Valentin Fuster, MD, PhD • Bruce Gelb, MD • Alison M. Goate, DPhil • Kurt Hirschhorn, MD • Yasmin L. Hurd, PhD • Philip J. Landrigan, MD, MSc • Helen S. Mayberg, MD • Diane E. Meier, MD • Eric J. Nestler, MD, PhD • Maria Iandolo New, MD • Peter Palese, PhD • Ramon E. Parsons, MD, PhD • Lynne D. Richardson, MD • Hugh A. Sampson, MD • Albert Siu, MD, MSPH • Barbara G. Vickrey, MD, MPH • Rachel Yehuda, PhD.
About the Mount Sinai Health System
Mount Sinai Health System is one of the largest academic medical systems in the New York metro area, with 48,000 employees working across eight hospitals, more than 400 outpatient practices, more than 600 research and clinical labs, a school of nursing, and a leading school of medicine and graduate education. Mount Sinai advances health for all people, everywhere, by taking on the most complex health care challenges of our time—discovering and applying new scientific learning and knowledge; developing safer, more effective treatments; educating the next generation of medical leaders and innovators; and supporting local communities by delivering high-quality care to all who need it.
Through the integration of its hospitals, labs, and schools, Mount Sinai offers comprehensive health care solutions from birth through geriatrics, leveraging innovative approaches such as artificial intelligence and informatics while keeping patients’ medical and emotional needs at the center of all treatment. The Health System includes approximately 9,000 primary and specialty care physicians and 11 free-standing joint-venture centers throughout the five boroughs of New York City, Westchester, Long Island, and Florida. Hospitals within the System are consistently ranked by Newsweek’s® “The World’s Best Smart Hospitals, Best in State Hospitals, World Best Hospitals and Best Specialty Hospitals” and by U.S. News & World Report's® “Best Hospitals” and “Best Children’s Hospitals.” The Mount Sinai Hospital is on the U.S. News & World Report® “Best Hospitals” Honor Roll for 2024-2025.
For more information, visit https://www.mountsinai.org or find Mount Sinai on Facebook, Twitter and YouTube.
Mount Sinai Study Reveals Genetic and Cellular Mechanisms of Crohn’s Disease
Mar 31, 2021 View All Press ReleasesResearchers Identify Opportunities to Advance Genomic Medicine
Jan 27, 2020 View All Press Releases